- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Analysis: APEC Nations Back Face-Saving Climate Plan
- Shift Into High-Quality Stocks Could Move Market Higher
- China: Low US Interest Rates Threaten Recovery
- Drug Study Questions Effectiveness of Merck's Drugs
- Buffett: I Haven't Bought AMEX Shares in Years
- Military Arms Race Dominates Dubai Air Show
- Disaster Film '2012' Drowns Rivals at Box Office
- Cities With the Most Home Price Reductions
- Cramer: 5 Earnings Reports to Watch Next Week
MOST SHARED
- U.S. May Wind Up Green With Envy
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Disaster Film '2012' Drowns Rivals at Box Office
- For Investors, The New Green Looks To Be White
- Dipping Into Green Investing
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- The Cost of Thanksgiving Dinner 2009
- Analysis: APEC Nations Back Face-Saving Climate Plan
Text Size 
Big pharma company Eli Lilly is coming under fire. CNBC's Pharmaceuticals Reporter Mike Huckman had the late breaking details on this morning’s “Squawk Box.” Huckman reported that
Eli Lilly [LLY
Loading...
()
] said sales of its top selling drug Zyprexa would be “stable” next year (the drug is used for schizophrenia and bipolar disorder).
But this morning--investors are skeptical about that forecast in the wake of back to back front page stories in the New York Times.
The Times reports that some patients have put on more than a hundred pounds from use of the drug. A plaintiffs' lawyer gave the times internal Lilly documents and emails suggesting the company tried to downplay those side effects.
Today the Times reports on marketing documents that indicate Lilly pushed use of the drug on elderly people with dementia--but was unapproved to do so.
Over the past few years--use of Zyprexa stopped growing as fast as it had been--because of lingering concerns over side effects like weight gain and diabetes.
Lilly says in a press release the emails and documents have been taken out of context..."these leaked documents do not accurately portray Lilly's conduct."
The threat to the Zyprexa franchise is pressuring Lilly shares ahead of the open this morning.
Analysts estimate Zyprexa is responsible for 1/3 to ½ of Lilly's profits.
Separately, Lilly is raising its bid for Icos [ICOS
Loading...
()
], set for a shareholder vote tomorrow, by two bucks to 34 dollars a share.
Less than two weeks ago Lilly CEO Sydney Taurel told Huckman he wasn't budging on the Icos price - that he considered it a full and fair offer.
- Where, what, how.
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
Data is a real-time snapshot *Data is delayed at least 15 minutes